<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460311</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Analytical Performance of a Multiplexed Microarray Assay for Rapid Identification and Quantification of a Multivalent mRNA Vaccine.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1144</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101144</ELocationID><Abstract><AbstractText>mRNA vaccines were highly effective in response to the COVID-19 pandemic, making them an attractive platform to address cancers and other infectious diseases. Many new mRNA vaccines in development are multivalent, which represents a difficulty for the standard assays commonly used to characterize the critical quality attributes of monovalent formulations. Here, we present a multiplexed analytical tool with nucleic acid microarray technology using the VaxArray platform that measures the identity and quantity of mono- and multivalent mixtures of naked mRNA and mRNA encapsulated in lipid nanoparticle formulations in under 2 h without any additional preparation steps, such as extraction or RT-PCR. Using a quadrivalent mixture of encapsulated mRNA constructs that encode for four unique proteins in a vaccine formulation, the VaxArray mRNA assay was demonstrated to be highly specific for each mRNA with sensitivity &lt; 1 µg/mL. The quantification of individual mRNAs within the lipid nanoparticle mixture resulted in a precision of ≤10% RSD and an accuracy of 100 ± 9%.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gerold</LastName><ForeName>Megan N</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0009-0000-9381-5839</Identifier><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toth</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Rebecca H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Rachel Y</ForeName><Initials>RY</Initials><Identifier Source="ORCID">0000-0002-7890-1605</Identifier><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadkarni</LastName><ForeName>Durgesh V</ForeName><Initials>DV</Initials><Identifier Source="ORCID">0000-0003-0733-4380</Identifier><AffiliationInfo><Affiliation>BioTherapeutics Pharmaceutical Sciences, Bioprocess Research &amp; Development, Pfizer, Inc., 875 Chesterfield Parkway West, Chesterfield, MO 63017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barua</LastName><ForeName>Sutapa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>BioTherapeutics Pharmaceutical Sciences, Pharmaceutical Research &amp; Development, Pfizer Inc., One Burtt Road, Andover, MA 01810, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>BioTherapeutics Pharmaceutical Sciences, Analytical Research &amp; Development, Pfizer, Inc., 875 Chesterfield Parkway West, Chesterfield, MO 63017, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowlen</LastName><ForeName>Kathy L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Erica D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>InDevR Inc., 6035 Longbow Dr, Suite 102, Boulder, CO 80301, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">identity</Keyword><Keyword MajorTopicYN="N">microarray</Keyword><Keyword MajorTopicYN="N">multivalent mRNA</Keyword><Keyword MajorTopicYN="N">nucleic acid</Keyword><Keyword MajorTopicYN="N">quantification</Keyword></KeywordList><CoiStatement>The authors disclose the following financial interests that could be viewed as potential competing interests: K.R. and E.D. are stockholders of InDevR, Inc. Other InDevR-affiliated authors are employees of InDevR, Inc., but declare no additional conflicts of interest. All Pfizer authors may have financial interests in the form of the company’s stock, stock options, and other employment-related long-term incentives.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460311</ArticleId><ArticleId IdType="pmc">PMC11511549</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101144</ArticleId><ArticleId IdType="pii">vaccines12101144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Macchia A., Ferrante D., Angeleri P., Biscayart C., Mariani J., Esteban S., Tablado M.R., de Quirós F.G.B. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years and Older in a Middle-Income Country. JAMA Netw. Open. 2021;4:e2130800. doi: 10.1001/jamanetworkopen.2021.30800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30800</ArticleId><ArticleId IdType="pmc">PMC8556631</ArticleId><ArticleId IdType="pubmed">34714342</ArticleId></ArticleIdList></Reference><Reference><Citation>Castelli J.M., Rearte A., Olszevicki S., Voto C., Del Valle Juarez M., Pesce M., Iovane A.N., Paz M., Chaparro M.E., Buyayisqui M.P., et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: Test negative, case-control study. BMJ. 2022;379:e073070. doi: 10.1136/bmj-2022-073070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-073070</ArticleId><ArticleId IdType="pmc">PMC9709697</ArticleId><ArticleId IdType="pubmed">36450402</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmani K., Shavaleh R., Forouhi M., Disfani H.F., Kamandi M., Oskooi R.K., Foogerdi M., Soltani M., Rahchamani M., Mohaddespour M., et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front. Public Health. 2022;10:873596. doi: 10.3389/fpubh.2022.873596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.873596</ArticleId><ArticleId IdType="pmc">PMC9459165</ArticleId><ArticleId IdType="pubmed">36091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallapaty S., Callaway E., Kozlov M., Ledford H., Pickrell J., Van Noorden R. How COVID vaccines shaped 2021 in eight powerful charts. Nature. 2021;600:580–583. doi: 10.1038/d41586-021-03686-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03686-x</ArticleId><ArticleId IdType="pubmed">34916666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavda V.P., Yao Q., Vora L.K., Apostolopoulos V., Patel C.A., Bezbaruah R., Patel A.B., Chen Z.-S. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front. Immunol. 2022;13:961198. doi: 10.3389/fimmu.2022.961198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.961198</ArticleId><ArticleId IdType="pmc">PMC9574046</ArticleId><ArticleId IdType="pubmed">36263030</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis L.M., Badkar A.V., Cirelli D., Combs R., Lerch T.F. The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists’ Perspective. J. Pharm. Sci. 2023;112:640–647. doi: 10.1016/j.xphs.2022.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.09.014</ArticleId><ArticleId IdType="pmc">PMC9482796</ArticleId><ArticleId IdType="pubmed">36130677</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorn C.R., Sharma D., Combs R., Bhujbal S., Romine J., Zheng X., Sunasara K., Badkar A. The journey of a lifetime—Development of Pfizer’s COVID-19 vaccine. Curr. Opin. Biotechnol. 2022;78:102803. doi: 10.1016/j.copbio.2022.102803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2022.102803</ArticleId><ArticleId IdType="pmc">PMC9433349</ArticleId><ArticleId IdType="pubmed">36162187</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.C., Dema B., Reyes-Sandoval A. COVID-19 vaccines: Breaking record times to first-in-human trials. NPJ Vaccines. 2020;5:34. doi: 10.1038/s41541-020-0188-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0188-3</ArticleId><ArticleId IdType="pmc">PMC7193619</ArticleId><ArticleId IdType="pubmed">32377399</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbier A.J., Jiang A.Y., Zhang P., Wooster R., Anderson D.G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 2022;40:840–854. doi: 10.1038/s41587-022-01294-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01294-2</ArticleId><ArticleId IdType="pubmed">35534554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball P. The lightning-fast quest for COVID vaccines—And what it means for other diseases. Nature. 2021;589:16–18. doi: 10.1038/d41586-020-03626-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-03626-1</ArticleId><ArticleId IdType="pubmed">33340018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorentzen C.L., Haanen J.B., Met Ö., Svane I.M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450–e458. doi: 10.1016/S1470-2045(22)00372-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(22)00372-2</ArticleId><ArticleId IdType="pmc">PMC9512276</ArticleId><ArticleId IdType="pubmed">36174631</ArticleId></ArticleIdList></Reference><Reference><Citation>Immuowatch RNA-Based Drug Products. 7th ed. Mab Designs; Bristol, CT, USA: 2023.  [(accessed on 3 October 2024)].  Available online:  https://www.mabdesign.fr/wp-content/uploads/2023/06/Immunowatch-Edition-7-RNA-based-drug-products.pdf.</Citation></Reference><Reference><Citation>Arevalo C.P., Bolton M.J., Le Sage V., Ye N., Furey C., Muramatsu H., Alameh M.G., Pardi N., Drapeau E.M., Parkhouse K., et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378:899–904. doi: 10.1126/science.abm0271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0271</ArticleId><ArticleId IdType="pmc">PMC10790309</ArticleId><ArticleId IdType="pubmed">36423275</ArticleId></ArticleIdList></Reference><Reference><Citation>Big mRNA players focus on flu vaccines. Nat. Biotechnol. 2022;40:1706. doi: 10.1038/s41587-022-01620-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01620-8</ArticleId><ArticleId IdType="pubmed">36477508</ArticleId></ArticleIdList></Reference><Reference><Citation>5 Years of Age and Older Bivalent Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine.  [(accessed on 3 October 2024)]; Available online:  https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer-StandingOrders-5yrs-Older-508.pdf.</Citation></Reference><Reference><Citation>Dolgin E. mRNA flu shots move into trials. Nat. Rev. Drug Discov. 2021;20:801–803. doi: 10.1038/d41573-021-00176-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00176-7</ArticleId><ArticleId IdType="pubmed">34635829</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur R.  Biopharma Reporter. William Reed Ltd.; Broadfield Park, West Sussex, UK:  [(accessed on 3 October 2024)]. Moderna Takes mRNA Influenza Candidate into Phase 3 Trials. Available online:  https://www.biopharma-reporter.com/Article/2022/06/07/moderna-takes-mrna-influenza-candidate-into-phase-3-trial.</Citation></Reference><Reference><Citation>Rosa S.S., Prazeres D.M.F., Azevedo A.M., Marques M.P.C. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine. 2021;39:2190–2200. doi: 10.1016/j.vaccine.2021.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.03.038</ArticleId><ArticleId IdType="pmc">PMC7987532</ArticleId><ArticleId IdType="pubmed">33771389</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson N.A.C., Kester K.E., Casimiro D., Gurunathan S., DeRosa F. The promise of mRNA vaccines: A biotech and industrial perspective. NPJ Vaccines. 2020;5:11. doi: 10.1038/s41541-020-0159-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-0159-8</ArticleId><ArticleId IdType="pmc">PMC7000814</ArticleId><ArticleId IdType="pubmed">32047656</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal G., Särnefält A., Kumar A. Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. NPJ Vaccines. 2021;6:53. doi: 10.1038/s41541-021-00317-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00317-4</ArticleId><ArticleId IdType="pmc">PMC8044082</ArticleId><ArticleId IdType="pubmed">33850138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyal G. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. NPJ Vaccines. 2022;7:50. doi: 10.1038/s41541-022-00470-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-022-00470-4</ArticleId><ArticleId IdType="pmc">PMC9072649</ArticleId><ArticleId IdType="pubmed">35513416</ArticleId></ArticleIdList></Reference><Reference><Citation>Poveda C., Biter A.B., Bottazzi M.E., Strych U. Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. Vaccines. 2019;7:131. doi: 10.3390/vaccines7040131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines7040131</ArticleId><ArticleId IdType="pmc">PMC6963847</ArticleId><ArticleId IdType="pubmed">31569760</ArticleId></ArticleIdList></Reference><Reference><Citation>Analytical Procedures for mRNA Vaccine Quality (Draft Guidelines) 2nd ed. USP-NF; North Bethesda, MD, USA: 2023.  [(accessed on 10 May 2023)].  Available online:  https://www.usp.org/sites/default/files/usp/document/our-work/biologics/documents/vaccine-mrna-guidelines-2.pdf.</Citation></Reference><Reference><Citation>Gao R.Y., Riley C.M., Toth E., Blair R.H., Gerold M.N., McCormick C., Taylor A.W., Hu T., Rowlen K.L., Dawson E.D. Rapid Identity and Quantity CQA Test for Multivalent mRNA Drug Product Formulations. Vaccines. 2022;10:1704. doi: 10.3390/vaccines10101704.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101704</ArticleId><ArticleId IdType="pmc">PMC9612012</ArticleId><ArticleId IdType="pubmed">36298569</ArticleId></ArticleIdList></Reference><Reference><Citation>Freyn A.W., Ramos da Silva J., Rosado V.C., Bliss C.M., Pine M., Mui B.L., Tam Y.K., Madden T.D., de Souza Ferreira L.C., Weissman D., et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol. Ther. 2020;28:1569–1584. doi: 10.1016/j.ymthe.2020.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.04.018</ArticleId><ArticleId IdType="pmc">PMC7335735</ArticleId><ArticleId IdType="pubmed">32359470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H., Bell K.N., Loker R.N. qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies. Mol. Ther. Methods Clin. Dev. 2021;20:152–168. doi: 10.1016/j.omtm.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtm.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7786041</ArticleId><ArticleId IdType="pubmed">33473355</ArticleId></ArticleIdList></Reference><Reference><Citation>Koetsier G., Cantor E.  Technical Note: A Practical Guide to Analyzing Nucleic Acid Concentration and Purity with Microvolume Spectrophotometers. New England BioLabs, Inc.; Ipswich, MA, USA: 2019.  [(accessed on 3 October 2024)].  Available online:  https://www.neb.com/-/media/nebus/files/application-notes/technote_mvs_analysis_of_nucleic_acid_concentration_and_purity.pdf.</Citation></Reference><Reference><Citation>Baldwin J., Piplani S., Sakala I.G., Honda-Okubo Y., Li L., Petrovsky N. Rapid development of analytical methods for evaluating pandemic vaccines: A COVID-19 perspective. Bioanalysis. 2021;13:1805–1826. doi: 10.4155/bio-2021-0096.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/bio-2021-0096</ArticleId><ArticleId IdType="pmc">PMC8516068</ArticleId><ArticleId IdType="pubmed">34645288</ArticleId></ArticleIdList></Reference><Reference><Citation>ModernaTX, Inc  A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to 24 Months.  [(accessed on 3 October 2024)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05743881.</Citation></Reference><Reference><Citation>ModernaTX, Inc  A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old.  [(accessed on 10 May 2023)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT05585632.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>